Brief: Grifols Gets FDA Approval To Start Phase 2 Trial With Immunoglobulin Eye Drops
21/05/2025 11:12
May 21 (Reuters) - Grifols SA GRLS.MC: GETS FDA APPROVAL TO START PHASE 2 TRIAL WITH IMMUNOGLOBULIN EYE DROP FOR DRY EYE DISEASE STUDY TO START IN Q3 Further company coverage: GRLS.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Grifols SA
See all newsSpanish stocks - Factors to watch on June 24
Brief: Grifols Approves Reduction Of Up To 10% Of Its Share Capital
Brief: Grifols Launches Fibrinogen Concentrate For Acute Bleeding Episodes In The U.S.
Brief: Grifols' Egypt Unit Adds €180 Mln Of Additional Investment In Project
Spanish stocks - Factors to watch on June 12